Tenet Healthcare (THC) Rises Higher Than Market: Key Facts

Tenet Healthcare (THC) closed the latest trading day at $166.26, indicating a +0.97% change from the previous session's end. The stock's change was more than the S&P 500's daily gain of 0.4%. Elsewhere, the Dow gained 0.28%, while the tech-heavy Nasdaq added 0.39%.Shares of the hospital operator witnessed a gain of 15.19% over the previous month, beating the performance of the Medical sector with its loss of 3.41% and the S&P 500's gain of 6.69%.Analysts and investors alike will be keeping a close eye on the performance of Tenet Healthcare in its upcoming earnings disclosure. The company is expected to report EPS of $2.84, up 22.94% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $5.15 billion, up 0.85% from the year-ago period.For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $12.69 per share and a revenue of $20.9 billion, representing changes of +6.82% and +1.12%, respectively, from the prior year.Any recent changes to analyst estimates for Tenet Healthcare should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. Consequently, upward revisions in estimates express analysts' positivity towards the company's business operations and its ability to generate profits.Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, there's been a 4.14% rise in the Zacks Consensus EPS estimate. Tenet Healthcare is currently sporting a Zacks Rank of #2 (Buy).Digging into valuation, Tenet Healthcare currently has a Forward P/E ratio of 12.98. This represents a premium compared to its industry's average Forward P/E of 11.41.Meanwhile, THC's PEG ratio is currently 1.2. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. The Medical - Hospital was holding an average PEG ratio of 1.25 at yesterday's closing price.The Medical - Hospital industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 59, finds itself in the top 24% echelons of all 250+ industries.The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Tenet Healthcare Corporation (THC): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks